Barbara Ryan, Deutsche Bank Securities senior pharmaceutical analyst, takes a look at the vital signs of big drug companies and weighs in on what to expect from the Supreme Court's ruling on President Obama's health care overhaul plan.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT